FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma
Annals of Oncology, ISSN: 0923-7534, Vol: 17, Issue: 11, Page: 1650-1655
2006
- 52Citations
- 37Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations52
- Citation Indexes52
- 52
- CrossRef27
- Captures37
- Readers37
- 37
Article Description
Background: The current study focuses on the prognostic value of pretreatment metabolic activity in metastases as measured with [ 18 F]fluorodeoxyglucose positron emission tomography (FDG-PET), as an indicator of survival in colorectal cancer. Patients and methods: In a prospective series of 152 patients with metastatic colorectal cancer, of whom 67 were treated with resection of metastases and 85 with chemotherapy, standardized uptake values (SUV) as measured with FDG-PET, were calculated prior to treatment. Survival probabilities were estimated by Cox proportional regression analysis. For Kaplan–Meier analysis SUV was stratified by the median value. Survival differences were assessed using the log-rank test. Results: SUV in metastases was a significant predictor for overall survival (hazard ratio 1.17, 95% confidence interval 1.06–1.30, P = 0.002), independent of the subsequent treatment. According to the median value of the patient population a low (SUV <4.26) and high uptake group (SUV >4.26) was defined. The median survival and the 2- and 3-year survival rates were 32 months, 59% and 45%, respectively, in the low-uptake group and 19 months, 37% and 28%, respectively, in the high-uptake group ( P = 0.017). Conclusion: A significant survival benefit was observed in patients with low FDG uptake in metastases of colorectal cancer.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S092375341938069X; http://dx.doi.org/10.1093/annonc/mdl180; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33750597875&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/16936185; https://linkinghub.elsevier.com/retrieve/pii/S092375341938069X; https://dx.doi.org/10.1093/annonc/mdl180
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know